In clinical trials, Moderna’s combination vaccine elicited higher immune responses against influenza (flu) virus and SARS-CoV-2 than licensed flu and Covid-19 vaccines in adults 50 years and older. The Phase III trial investigated mRNA-1083, an investigational combination vaccine against influenza and Covid-19. mRNA-1083 comprises… Read More
Researchers at the National Institutes of Health have identified antibodies targeting a hard-to-spot region of the influenza virus, shedding light on the relatively unexplored ‘dark side’ of the neuraminidase (NA) protein head. The antibodies target a region of the NA protein that is common among many… Read More
The Oxford Vaccine Group at the University of Oxford, UK, has launched the LEGACY03 study into human immunity, aimed to improve the design of seasonal vaccines and allow targeting by age group. This study, funded by the Medical Research Council, will test the responses of cells… Read More
The Native Antigen Company (part of LGC Clinical Diagnostics) has launched its latest range of influenza antigens for the southern hemisphere’s 2023 flu season. The latest influenza antigens will help support development of vaccines and diagnostics as part of the ongoing vaccine reformulation programme, helping to ensure… Read More
Getting an annual flu shot may be associated with a lower risk of stroke, Spanish researchers have claimed. The findings, from a study conducted at the University of Alcalá in Madrid, have been published in the journal Neurology. The observational study suggests that those who have a flu shot have… Read More
The National Institutes of Health (NIH) has launched a Phase I clinical trial for a potential universal flu vaccine. The trial will assess the vaccine candidate BPL-1357 which has been developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID). The candidate is a… Read More
